Agarophyton Chilensis Extract Composition for Prostate Cell Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective therapies for the prevention and treatment of prostate cancer, particularly in its early and advanced stages, with existing treatments either being ineffective or associated with significant side effects, and no known natural products are available for this purpose.
Innovation Solution
The use of an oily extract from Agarophyton chilensis, rich in specific fatty acids, is formulated into a pharmaceutical composition that demonstrates antiproliferative effects on prostate cancer cells without harming non-tumor cells, offering potential for both treatment and prevention of prostate cancer and benign prostatic hyperplasia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional treatments (radical prostatectomy and radiation therapy) are used for localized prostate cancer, then tumor removal is achieved, but more than 30% of patients require additional treatment within 5-10 years indicating treatment recurrence
Solution Approach 1:
The patent applies preliminary action by using Agarophyton chilensis extract as a preventive therapy before prostate cancer develops or progresses to advanced stages. The extract is administered to inhibit initial tumor formation and progression, preventing the need for radical prostatectomy and subsequent recurrent treatments. This proactive approach addresses the reliability issue by stopping disease progression before it requires repeated invasive interventions.
2Reliability
If androgen deprivation therapy (ADT) is used for advanced prostate cancer, then tumor progression is initially controlled, but most patients develop castration-resistant phenotype within 18-24 months requiring palliative chemotherapy
Solution Approach 1:
The patent applies preliminary anti-action by using Agarophyton chilensis extract to counteract prostate cancer progression before castration-resistant phenotype develops. The extract contains compounds that preemptively inhibit the molecular pathways leading to resistance, thereby extending the duration of effective disease control beyond the typical 18-24 month limitation of ADT alone.
Solution Approach 2:
The patent employs composite materials by combining multiple bioactive compounds from Agarophyton chilensis (including fatty acids, phenolic compounds, and other metabolites) into a synergistic pharmaceutical formulation. This composite approach enhances disease control duration by targeting multiple pathways simultaneously, preventing the development of resistance mechanisms that would otherwise limit ADT effectiveness.
3Reliability
If Sa-reductase inhibitors (finasteride and dutasteride) are used for prostate cancer prevention, then preventive effect is achieved, but risk of high-grade CaP increases leading to FDA non-approval
Solution Approach 1:
The patent applies this principle by using natural compounds from Agarophyton chilensis that provide preventive effects without the long-term harmful accumulation issues of synthetic Sa-reductase inhibitors. The natural extract offers a safer alternative that achieves prevention without increasing high-grade cancer risk, making it suitable for FDA approval and long-term preventive use.
Solution Approach 2:
The patent applies parameter changes by modifying the chemical composition approach - transitioning from synthetic Sa-reductase inhibitors to a complex mixture of natural compounds from Agarophyton chilensis. This parameter change in the chemical profile provides preventive efficacy while eliminating the harmful side effect of increased high-grade CaP risk associated with synthetic inhibitors.
4Reliability
If existing natural products (selenium, vitamin E, non-steroidal drugs, toremifene) are used for prostate cancer prevention, then some preclinical activity is observed, but clinical trials show insufficient evidence of preventive effect
Solution Approach 1:
The patent applies composite materials by formulating a complex mixture of bioactive compounds from Agarophyton chilensis rather than using single isolated compounds. This composite approach, similar to traditional herbal medicines, provides synergistic effects that demonstrate both preclinical and clinical preventive activity, overcoming the insufficiency of single-compound approaches in previous trials.
Data Source
AI summary
The invention relates to a pharmaceutical composition of an extract of Agarophyton chilensis, with antiproliferative effect in prostate cancer, comprising(a) 0.1 to 90% of an oleoresin of Agarophyton chilensis, with the following major components: palmitic acid, arachidonic acid, oleic acid, stearic acid, meristic acid, linoleic acid; and(b) 10 to 99.9% excipients and formulation aids for different pharmaceutical forms.And its use to prepare a drug for the treatment or prevention of prostate cancer and other hyperproliferative states of prostate tissue cells.